Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Other Operating Expenses (2017 - 2024)

Summit Therapeutics filings provide 8 years of Other Operating Expenses readings, the most recent being $205000.0 for Q4 2024.

  • Quarterly Other Operating Expenses rose 14.53% to $205000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $205000.0 through Sep 2025, down 28.57% year-over-year, with the annual reading at $313000.0 for FY2024, 68.73% down from the prior year.
  • Other Operating Expenses hit $205000.0 in Q4 2024 for Summit Therapeutics, up from -$264000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $5.5 million in Q3 2022 and bottomed at -$264000.0 in Q3 2024.
  • Average Other Operating Expenses over 4 years is $981833.3, with a median of $239000.0 recorded in 2023.
  • Peak annual rise in Other Operating Expenses hit 688.89% in 2024, while the deepest fall reached 199.62% in 2024.
  • Summit Therapeutics' Other Operating Expenses stood at $859000.0 in 2020, then soared by 31.9% to $1.1 million in 2022, then crashed by 84.2% to $179000.0 in 2023, then increased by 14.53% to $205000.0 in 2024.
  • Per Business Quant, the three most recent readings for SMMT's Other Operating Expenses are $205000.0 (Q4 2024), -$264000.0 (Q3 2024), and $159000.0 (Q2 2024).